



Supplementary Figure 4, related to Figures 4 and 6

(A, B) IHC for α SMA in tumors arising from subcutaneous co-injection of KPC cells together with PSCs expressing control or *Vhl* sgRNA. (A) Representative image. (B) Quantification of α SMA+ area. N=6 (PSC Ctrl), N=9 (PSC *Vhl* sg2). P-values were calculated by Student's t-test. (C) PSC/Tumor organoid co-culture experiment. PDAC organoids expressing Luciferase were cultured alone or together with PSCs expressing Ctrl or *Vhl* sgRNA for 4 days. Growth was assessed by measuring Luciferase signal. (D) Subcutaneous co-injection of KPC cells together with PSCs expressing control of *Vhl* sgRNA. One week later, tumors were treated with IgG or anti-IL6 monoclonal antibodies. Treatment effect was assessed by comparing tumor volumes at endpoint and the start of treatment. (E) GSEA for Hallmarks Angiogenesis signature comparing PSCs cultured in normoxia or hypoxia (left), or PSCs expressing control or *Hif1a* sgRNA and cultured in hypoxia for 48h (right). N=3 biological replicates. (F, G) Assessment of CD31+ endothelial cells by flow cytometry (F) or IHC (G) in tumors arising from subcutaneous co-injection of KPC cells together with PSCs expressing control or *Vhl* sgRNA. (H) Correlation of the number of CD31+CD45- cells with tumor weight in tumors arising from subcutaneous co-injection of KPC cells together with PSCs expressing control or *Vhl* sgRNA that were treated with IgG control or anti-VEGFR2 monoclonal antibodies.